衰老对炎症性肠病患者英夫利西单抗暴露与应答的影响
该回顾性病例对照研究纳入104例接受英夫利西单抗诱导治疗的炎症性肠病患者(46例≥65岁),建立群体药代动力学模型评估年龄对暴露、疗效和安全性的影响。结果显示老年与非老年患者英夫利西单抗暴露无显著差异,w14 trough浓度15.6 mg/L与50%内镜缓解概率相关,且暴露不是不良事件风险因素。
要点
- 老年与非老年患者英夫利西单抗暴露无显著差异,可使用相同的TDM谷浓度目标。
- w14谷浓度15.6 mg/L与w6-w22内镜缓解50%概率相关,不受年龄影响。
- 严重不良事件和恶性肿瘤风险随年龄增长而增加,但与英夫利西单抗暴露无关。
核心结论
- 老年炎症性肠病患者英夫利西单抗暴露和内镜缓解与非老年患者相似,可采用相同的TDM谷浓度目标。
- 严重不良事件和恶性肿瘤风险随年龄增加,但与英夫利西单抗暴露无关。
研究设计与样本
- 回顾性病例对照研究,纳入104例接受英夫利西单抗诱导治疗的炎症性肠病患者(46例≥65岁)。
- 建立二室群体药代动力学模型估算个体药代参数,采用logistic回归分析暴露与内镜缓解关系,重复时间-事件模型描述安全性事件风险。
主要发现
- 英夫利西单抗清除率随年龄增长、血清白蛋白升高、去脂体重降低、C反应蛋白降低及无免疫原性而降低。
- 老年与非老年患者英夫利西单抗暴露无显著差异。
- 无论年龄,w14英夫利西单抗谷浓度15.6 mg/L与w6-w22内镜缓解50%概率相关。
- 诱导治疗期间英夫利西单抗暴露不是(严重)不良事件的风险因素。
- 严重不良事件和恶性肿瘤风险分别随年龄每增加1岁而增加2%和7%;合并免疫调节剂使感染风险增加958%,与年龄无关。
关键数值与推荐
- w14英夫利西单抗谷浓度15.6 mg/L对应w6-w22内镜缓解50%概率。
- 老年与非老年患者可使用相同的英夫利西单抗谷浓度TDM目标。
- 严重不良事件风险随年龄每增加1岁增加2%,恶性肿瘤风险增加7%。
- 合并免疫调节剂使感染风险增加958%,与年龄无关。
临床怎么用
- 老年炎症性肠病患者可采用与非老年患者相同的英夫利西单抗TDM谷浓度目标。
- 英夫利西单抗暴露不是不良事件风险因素,不应因担心安全性而降低老年患者暴露。
- 老年患者应关注年龄相关的严重不良事件和恶性肿瘤风险,合并免疫调节剂时需警惕感染风险增加。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Controversies regarding infliximab treatment in elderly patients with inflammatory bowel diseases remain. We evaluated the effect of patient's age on infliximab exposure, efficacy and safety. METHODS: Retrospective case-control data of patients receiving infliximab induction treatment were analysed. A population pharmacokinetic model was developed to estimate individual pharmacokinetic parameters. A logistic regression model was used to investigate the effect of exposure on endoscopic remission. Repeated time-to-event models were developed to describe the hazard of safety events over time. RESULTS: A total of 104 patients (46 elderly, ≥65 years) were included. A two-compartment population pharmacokinetic model with linear elimination adequately described the data. Infliximab clearance decreased with older age, higher serum albumin, lower fat-free mass, lower C-reactive protein and absence of immunogenicity. Yet, infliximab exposure was not significantly different between elderly and nonelderly. Regardless of age, an infliximab trough concentration at week (w)14 of 15.6 mg/L was associated with a 50% probability of attaining endoscopic remission between w6 and w22. Infliximab exposure during induction treatment was not a risk factor of (severe) adverse events. The hazard of severe adverse events and malignancy increased by 2% and 7%, respectively, with increasing year of age. Concomitant immunomodulator use increased the hazard of infection by 958%, regardless of age. CONCLUSIONS: Elderly patients attained infliximab exposure and endoscopic remission similarly to nonelderly patients. Therefore, the same infliximab trough concentration target can be used in therapeutic drug monitoring. The hazards of severe adverse events and malignancy increased with age, but not with infliximab exposure.
引用
- Kantasiripitak W, Verstockt B, Alsoud D, et al. The effect of aging on infliximab exposure and response in patients with inflammatory bowel diseases. Br J Clin Pharmacol. 2021. PMID: 33604964. doi:10.1111/bcp.14785
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。